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Abstract
Mucinous cystic neoplasms of the liver and extrahepatic biliary tree have recently been 
re-defined by WHO as epithelial cystic tumours with ovarian-type mesenchymal stroma. 
Correct recognition of these tumours can be difficult because of their rarity and, conse-
quently, lack of awareness by the medical team. Radiological evaluation, including ultra-
sonography, computed tomography, magnetic resonance imaging and, upon necessity, 
positron emission tomography, can yield the correct diagnosis. Radical surgical resection 
with tumour-free margins is the mainstay of treatment. Adequate treatment approach 
can be very rewarding, bringing prolonged survival. Here we discuss the up-to-date 
concepts of definition and classification, theoretical views on tumour origin along with 
practical issues of clinical presentation, diagnostics, treatment and prognosis.
Keywords: mucinous cystic neoplasm, liver, liver tumour, biliary cystadenoma,  
biliary cystadenocarcinoma
1. Introduction
Mucinous cystic neoplasms of the liver [1], formerly known as bile duct/biliary cystadenoma 
and biliary cystadenocarcinoma [2], represent an enigmatic entity, characterised by unknown 
origin and peculiar morphology including the presence of ovarian-type stroma. Clinically, 
these tumours are important albeit rare. Mucinous cystic neoplasms of the liver can be diag-
nostically challenging because of several reasons, including (1) prolonged clinical course sug-
gesting a benign disease or even harmless liver cyst; (2) controversial radiologic presentation; 
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and (3) insufficient experience of the involved medical team. Consequently, it might be dif-
ficult to select the best treatment. Lack of awareness of these unusual tumours is an important 
cause of diagnostic and surgical mistakes. To enhance the knowledge of medical society on 
the mucinous cystic neoplasms of the liver, here we aim to summarise contemporary data 
on these tumours, including the current definition and classification [1], the recent molecu-
lar genetic findings [3, 4] as well as the practical issues of clinical presentation, diagnostic 
approach, treatment and prognosis.
2. Definition and evolution of the concept
Currently, mucinous cystic neoplasms of the liver are defined as epithelial cystic tumours asso-
ciated with ovarian-type mesenchymal stroma. They are further subclassified by (1) presence or 
absence of invasion and (2) in non-invasive tumours—by the highest grade of epithelial atypia 
[1]. Thus, four entities are obtained (Table 1). Although intrahepatic location predominates, 
mucinous cystic neoplasms with true ovarian-type stroma can primarily develop in extrahe-
patic biliary ways [5, 6] or show extrahepatic extension [7].
The previous classification by WHO (2000) included bile duct cystadenoma/cystadenocar-
cinoma, defined as cystic tumours, that were lined by mucus-secreting or, less frequently, 
serous epithelium [2]. Stroma was not set as a diagnostic criterion.
Considering the current WHO definition [1] in the context of preceding classifications and 
morphology, three aspects must be kept in mind.
2.1. Diagnostic importance of the ovarian-type stroma
Mucinous cystic neoplasms of the liver were formerly referred to as bile duct/biliary cyst-
adenoma and cystadenocarcinoma. However, the presence of ovarian-type stroma was not 
mandatory in the preceding entities. It was present in the mucinous type of benign cystad-
enomas, but was absent from the serous type of biliary cystadenomas [2] as well as from a 
subfraction of cystadenocarcinomas [8]. In contrast, currently only tumours with ovarian-
type subepithelial stroma are classified as mucinous cystic neoplasms [1]. The cases lacking 
the specific stroma could represent intraductal papillary neoplasms of bile ducts with marked 
Biologic potential Diagnosis ICD-O code
Non-invasive mucinous cystic neoplasms 
of the liver
Mucinous cystic neoplasm with low-grade 
intraepithelial neoplasia
8470/0
Mucinous cystic neoplasm with intermediate-grade 
intraepithelial neoplasia
8470/0
Mucinous cystic neoplasm with high-grade 
intraepithelial neoplasia
8470/2
Mucinous cystic neoplasms of the liver with 
an invasive component
Mucinous cystic neoplasm with an associated 
invasive carcinoma
8470/3
Table 1. Classification of the mucinous cystic neoplasms of the liver [1].
Topics in the Surgery of the Biliary Tree98
cystic changes [1]. The rearrangement of classification is in accordance with the previously 
well-known observation that biliary cystadenocarcinoma without ovarian-type stroma has 
distinctly worse prognosis [8–10] (it must be noted that contrary and neutral reports also have 
been published: see [11, 12], respectively) and is more frequently observed in males [8, 11].
2.2. Extent of mucus secretion
The neoplastic epithelium in fact may lack mucus production [1, 4]. Still, neoplasms showing 
ovarian-type stroma are not classified as serous cystadenomas [1].
2.3. Criteria to identify malignant cases
In the current classification, invasive and non-invasive tumours are clearly separated. In con-
trast, the preceding diagnostic criteria of biliary cystadenocarcinoma included invasion, cellular 
atypia, and mitotic activity to recognise a malignancy. Although invasion was underlined as the 
hallmark of malignant course, presence of cell atypia and mitoses also justified the diagnosis 
of carcinoma [2]. Currently, non-invasive cases showing anaplastic cell morphology would be 
classified as mucinous cystic neoplasms with high-grade intraepithelial neoplasia [1].
Unfortunately, terminological controversies and disagreements still remain. Although the 
current WHO classification redefined mucinous cystic neoplasms already on 2010, the 
preceding terms of biliary cystadenoma and cystadenocarcinoma are still in use [5, 13–15]. 
Ovarian-type stroma has been neglected as a diagnostic criterion, e.g., in a recent (2015) multi-
centric study only 33.3% of the evaluated biliary cystic tumours actually had this feature [11]. 
Some research teams have expressed disagreement with the present classification [5]. There 
are repeated discussions on cases lacking both ovarian-type stroma and communication with 
biliary ducts—a separate entity has been hypothesised [16].
3. Epidemiology
Mucinous cystic neoplasms of the liver are rare tumours. Previously, incidence of biliary cyst-
adenoma was estimated to range between 1:20,000 and 1:100,000, while incidence of biliary 
cystadenocarcinoma was reported to be 1:10 million [10]. Considering, that cases of biliary 
cystadenocarcinoma without ovarian-type stroma are reclassified as intraductal papillary 
neoplasms and non-invasive tumours showing cell anaplasia—as mucinous cystic neoplasms 
with high-grade intraepithelial neoplasia, the true incidence of malignant mucinous cystic 
neoplasms of the liver is even lower. The incidence of benign tumours also might change 
in accordance to the current (2010) WHO classification. Non-invasive mucinous cystic neo-
plasms of the liver that were previously diagnosed a biliary cystadenocarcinomas on the basis 
of cell atypia and mitotic activity, would be transferred to the benign group, increasing it, 
albeit slightly [1, 2]. On the contrary, the rare [10] serous type of biliary cystadenoma, defined 
by the previous WHO classification (2000), was known to lack ovarian-type stroma and 
nowadays would be excluded from the group of mucinous cystic neoplasms of the liver [1, 2]. 
Considering the whole group of mucinous cystic neoplasms with ovarian-type stroma, 25% 
of cases that were previously diagnosed as hepatobiliary cystadenoma/cystadenocarcinoma 
were reclassified as other entities according to the current WHO classification [15].
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Geographic differences have been highlighted by Zen et al. [17]. Comparing the numbers of 
intraductal papillary neoplasm of bile ducts and mucinous cystic neoplasm of the liver in med-
ical institutions of Seoul, Seattle and London, the ratios were 5.7:1; 1:3.0 and 1:6.3, respectively. 
In Eastern countries, intraductal papillary neoplasms are significantly more frequent [17].
In a recent large study, mucinous cystic neoplasms with ovarian-type stroma accounted 
for 11% of resected cystic liver lesions in a single institution [15]. However, this proportion 
should not be applied to all liver cysts found by radiologic investigation as only a small frac-
tion of liver cysts needs surgical treatment [9, 18, 19]. Even the frequently cited assessment 
that mucinous cystic neoplasms constitute 5% of cystic liver lesions [13, 19, 20] is known to 
be an overestimate [18] otherwise the incidence of biliary mucinous cystic tumours would 
exceed the occurrence of cholangiocarcinoma which is not observed. Instead, mucinous cystic 
neoplasms might represent 5% of symptomatic liver cysts referred for surgical treatment. In 
1996–1997, biliary cystadenocarcinoma accounted for 0.18% of all liver tumours registered 
by Japanese Liver Cancer Study Group [9]. However, it has been noted that mucinous cystic 
neoplasms are rare in Japan [21]. Currently, invasive mucinous cystic neoplasms constitute 
0.41% of hepatic carcinomas [19].
Although the demographic characteristics of the patients vary slightly depending on the clas-
sifications (Table 2), there are some essential general trends, including a strong female pre-
ponderance, predominant occurrence in middle-aged people and earlier age of diagnostics in 
benign/non-invasive cases.
4. Tumour origin and tissue structure
The presence of ovarian-type mesenchymal stroma raises questions on the origin of mucinous 
cystic neoplasms of the liver. The correct hypothesis should explain both the presence of this 
unusual feature and the structural similarity with mucinous cystic tumours of the pancreatic 
Feature Mucinous cystic neoplasms of the 
liver1
Biliary cystic tumours2
Non-invasive Invasive Cystadenoma Cystadenocarcinoma
Gender: proportion of 
female patients










Mean age, years 45 [1] 59 [1] 40.6; range, 30–51 [24]
45; range, 2–87 [8]
51.3; range, 41–63 [24]
59; range, 24–90 [8]
1According to WHO Classification of Tumours of the Digestive System, 2010 [25].
2According to World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of the Digestive 
System, 2000 [26].
Table 2. Demographic characteristics of mucinous cystic neoplasms of the liver.
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gland and retroperitoneal space showing similar stroma [27]. During embryogenesis, ectopic 
ovarian rests might develop in the liver, along biliary tree, in the pancreas or retroperitoneal 
tissues and stimulate the proliferation of adjacent biliary or pancreatic ducts by synthesis of 
growth factors [9, 28]. Indeed, during embryonic development, gonads initially are located 
directly under the diaphragm, dorsally to the liver and pancreatic tail, and only later they 
descend to the typical anatomic location seen in adults. The local morphologic appearance of 
embryonic peritoneal lining with swollen, activated-looking cells is also suspected to be an 
evidence of interaction between gonadal primordia and developing liver/pancreas, situated 
just across peritoneal cavity [29].
Origin from intrahepatic peribiliary glands has been preferred by some authors, based on 
morphological similarity, presence of endocrine cells both in mucinous cystic tumours and in 
peribiliary glands, and a huge autopsy investigation on 938 livers [1, 30]. In the given autopsy 
study reported by Sato et al., cystic and micropapillary changes in peribiliary glands were 
sought for and subjected to morphological and immunohistochemical analysis. Cystic glands 
were found in 4% of the examined livers while micropapillary lesions were present in 1%, 
but showed association with an invasive adenocarcinoma in a single case. Micropapillary 
areas exhibited marked mucus secretion, up-regulation of cyclin D1 and higher proliferative 
fraction by Ki-67, suggesting that these cell groups possessed a premalignant potential [30].
The peribiliary origin of mucinous cystic neoplasms of the liver seems to be the preferable 
explanation for the parallels with analogous pancreatic tumours. Biliary tract along with 
peribiliary glands has considerable structural similarity with pancreatic ducts and acini. 
Indeed, the biliary tree has even been designated as “incomplete pancreas”. The structural 
similarity is reflected in several pathologies (Table 3), not limited to mucinous cystic neo-
plasms [27]. The peribiliary glands could also eventually receive stimulation by ectopic ovar-
ian stroma—thus, both the aforementioned theories fuse together.
However, not all scientists support the hypothesis of ectopic ovarian tissues. Although the 
morphology of the specific mesenchymal component closely resembles ovarian stroma, there 
is also a remarkable similarity to embryonal tissues that are destined to form gallbladder or 
foregut [10]. The stromal immunophenotype is largerly unspecific, characteristic for myofi-
broblasts. Hormone receptor expression, including both oestrogen and progesterone recep-
tors, has been found in human embryonic stem cells [33] as well as in abdominal fibromatosis 
[34], not only in the stroma of ovaries. Thus, according to Ockham’s razor, simpler explana-
tion might include origin from peribiliary glands influenced by embryonal-like fibroblasts. 
Such view allows considering not only congenital but also acquired origin as proposed by 
Cruickshank and Sparshott [35], possibly a response to a focal injury or oestrogen-containing 
oral contraceptives [10, 18]. Indeed, a significant fraction of patients has history of obesity, 
heavy alcohol use, or hormone-related therapy [36].
Research team of D’Errico found that biliary cystadenocarcinomas co-expressed high levels 
of biliary cytokeratins (by immunohistochemistry) and albumin mRNA (by in situ hybridisa-
tion). This might indicate either tumour origin from pluripotent stem cells or re-acquisition 
of embryonal features. In situ hybridisation for albumin mRNA was proposed to distinguish 
between cystadenomas and cystadenocarcinomas; the association with malignancy might 
rather indicate dedifferentiation and not an evidence of the origin of biliary mucinous cystic 
neoplasms [37].
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5. Morphology: from gross findings to the molecular landscape
5.1. Gross structure
Grossly, the tumours represent a single cyst or a multilocular cystic lesion: a dense group of 
several cysts recognised by the cyst-in-cyst appearance or the presence of internal septations [1, 
21]. Multilocular structure (see Figure 1) predominates, in contrast to (1) simple cysts lacking 
internal septations and (2) intraductal papillary neoplasms exhibiting multicystic appearance: 
a grape-like cluster of adjacent cysts [21]. Thus, among 20 mucinous cystic neoplasms of the 
liver and extrahepatic bile ducts, there were 2 unilocular and 18 multilocular neoplasms [5]. 
Pathogenesis and characteristics Biliary diseases Pancreatic diseases
Pre-invasive flat intraepithelial neoplasia, 
representing a precursor of a solid invasive 
tumour
Biliary intraepithelial neoplasm: 
the precursor of nodular 
sclerosing cholangiocarcinoma
Pancreatic intraepithelial 
neoplasm: the precursor 
of pancreatic ductal 
adenocarcinoma
Grossly visible, mass forming, primarily 
intraductal neoplasms that can lead to duct 
obstruction with papillary tumour masses 
and secondary cystic dilation of obstructed 
ducts, followed by intracystic tumour growth. 
Invasive component can develop
Intraductal papillary neoplasm of 
bile ducts
Intraductal papillary mucinous 
neoplasm of pancreas
Presence of gross cysts Frequent, secondary to duct 
dilation
Frequent, secondary to duct 
dilation
Involvement and dilation of ducts Frequent Frequent
Mucus secretion Frequent Frequent
Ovarian-type stroma Absent Absent
Prognosis Can progress to an aggressive 
invasive cancer
Can progress to an aggressive 
invasive cancer
Patients Males and females Males and females
Mucinous cystic neoplasms: cystic tumours 
with subepithelial ovarian-type stroma
Hepatobiliary mucinous cystic 
neoplasm
Pancreatic mucinous cystic 
neoplasm
Presence of gross cysts Always Always
Involvement and dilation of ducts Rare or absent Rare or absent
Mucus secretion Frequent but variable Frequent but variable
Ovarian-type stroma Always Always
Prognosis Good after complete surgical 
resection
Good after complete surgical 
resection
Patients Mostly: middle-aged females Mostly: middle-aged females




Mass-forming type 1 
autoimmune pancreatitis
Table 3. Biliary diseases with pancreatic counterparts [9, 27, 31, 32].
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The frequency of multilocular tumours is estimated to be 84%. In non-invasive cases, fibrous 
capsule delineates the whole tumour. Even invasive tumours mostly show only a limited 
spread within the fibrous pseudocapsule [38]. Extrahepatic development is less frequently 
seen, e.g., in a series of 20 cases, only 4 patients had an extrahepatic tumour [5]. The fre-
quency of extrahepatic mucinous cystic neoplasms of biliary tree has been variably esti-
mated to range between 3 and 20% [5, 39], averaging 10% of all mucinous cystic neoplasms 
of liver [13].
The cysts usually contain clear fluid, but occasionally thick mucus or haemorrhagic content 
can be found [1]. The tumour size is variable, reported to range from 1.2 to 40 cm in diam-
eter [38]. A grossly evident communication with larger bile ducts is not typical. If present, 
such feature may suggest the diagnosis of an intraductal papillary neoplasm of bile ducts 
[31]. Papillary areas and mural nodules (Figure 1) should be identified grossly, described 
in the surgical pathology report and sampled extensively as these foci are suspicious for 
malignant change [1]. In contrast, trabeculation of the inner surface can be seen even in 
cystadenomas [10].
Figure 1. Mucinous cystic tumour of the liver. A, computed tomography findings. Note the huge cyst with internal 
septations (arrowhead). B, gross view. Note the nodule (arrow) harbouring invasive malignancy. Widespread 
haemorrhage (star) also is present. C, intense expression of cytokeratin 20 in an area of intestinal differentiation, showing 
rich presence of goblet cells. Immunoperoxidase (IP), original magnification (OM) 100×. D. Intense nuclear expression 
of progesterone receptors in the ovarian-type stroma. Note the absence of reactivity in the epithelium. IP, OM 400×.
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5.2. Microscopic characteristics of epithelium
Histologically, the cysts are lined by epithelium. The height and cytoplasmic structure of 
epithelial cells varies widely: from cylindrical to flat, from mucus secreting to cases in which 
only a small amount of mucus can be highlighted by mucicarmine stain or tumours with 
serous appearance of epithelium [1]. Typical epithelium is cuboidal, columnar or tall, with 
pale eosinophilic cytoplasm and basally located nuclei [10]. Mucus secretion is not marked in 
significant fraction of the considered tumours albeit the entity is designated as mucinous cys-
tic neoplasms of the liver [4]. For instance, among 20 cases of mucinous cystic tumours of the 
liver and extrahepatic bile ducts, 18 tumours were predominantly composed of cuboidal or 
low columnar epithelium that was similar to the lining of bile ducts. Only two cases showed 
rich mucus secretion along with intestinal differentiation and presence of goblet cells [5]. 
Among 36 mucinous cystic neoplasms of the liver and extrahepatic biliary tree, non-mucinous 
epithelium was predominant in 50% cases [15]. Gastric, intestinal (Figure 1) or squamous dif-
ferentiation can also occur. Basement membrane is present in non-invasive cases [1].
Enlarged, hyperchromatic, crowded nuclei, loss of nuclear polarity and presence of mitoses 
indicate intraepithelial neoplasia. High-grade intraepithelial neoplasia is characterised by glan-
dular crowding, significant nuclear pleomorphism and brisk mitotic activity. The architectural 
disarray in high-grade intraepithelial neoplasia manifests both as papillary elevations and crypt-
like invaginations into the stroma. The latter must be distinguished from true invasive growth.
Invasion is the hallmark of malignancy and must be acknowledged in the diagnosis as a muci-
nous cystic neoplasm with an associated invasive carcinoma [1]. The frequency of invasive 
carcinoma in mucinous cystic neoplasms of the liver or extrahepatic biliary ways has been 
variably reported to be 2 [17]; 6 [15]; 10 [4] or 15.4% [40]. In some series, invasion was not found, 
e.g., there were no invasive carcinomas among 29 mucinous cystic neoplasms described by 
Zen et al., although a single case of so-called carcinoma in situ was identified [21]. In contrast, 
the proportion of malignant cases by the preceding WHO classification (2000) was as high as 
38.5% [41]. If present, invasive areas tend to be small, e.g., in the only 2 (of 36 investigated 
mucinous cystic neoplasms of the liver or extrahepatic biliary tree) invasive cases, the invasive 
areas measured merely 7–8 mm [15].
5.3. Molecular features in correlation with morphology
The amount of cytoplasmic mucus is an interesting and significant feature of neoplastic epi-
thelium (Table 4). As mentioned, in a significant fraction of cystic tumours, mucinous epithe-
lium is not the dominant type: it occupies less than 50% of surface and can be as limited as 
10%. Nevertheless, such cases are still diagnosed as mucinous cystic neoplasms of the liver 
if ovarian-type stroma is present. Although the terminology might seem slightly confusing, 
sufficient experience of pathologist will easily allow overcoming the diagnostic problems. 
However, there is a far more important aspect: the degree of mucinous differentiation is 
shown to parallel the frequency of KRAS mutations and of invasive carcinoma [4]. Already 
earlier, intestinal metaplasia with the presence of goblet cells (Figure 1) has been acknowl-
edged as a premalignant lesion [10].
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Thus, in a study group of 15 mucinous cystic neoplasms of the pancreas and liver, there were 6 
cases with marked mucus secretion while in the remaining 9 cases less than 50% of epithelium 
showed obvious mucus in the cytoplasm. Invasive carcinoma was found in two cases, both 
from mucus-rich group. A single case of high-grade intraepithelial neoplasia also was found 
within the mucus-rich group. The tumours with limited amount of mucus featured only low-
grade intraepithelial neoplasia [4]. Analogous findings have been reported also by Albores-
Saavedra et al. [42] and Zhelnin et al. [43]. The first of these studies was devoted to pancreatic 
mucinous cystic neoplasms—the counterpart of hepatic tumours. Among the evaluated 31 
cases, 22 showed abundant mucus production and 6 of them were associated with invasive 
carcinoma. In contrast, there was no invasive component in any of the nine cases presenting 
with non-mucinous cuboidal or low columnar epithelium [42]. Subsequently, in a large cohort 
comprising 136 pancreatic and hepatic mucinous cystic neoplasms, high-grade intraepithe-
lial neoplasia (8 tumours) or invasive carcinoma (14 patients) were found only among cases 
with marked mucus secretion (defined as presence of microscopically visible mucus in more 
than 50% of neoplastic epithelial cells). There were also 58 cases with predominantly (>50%) 
non-mucinous epithelium, and no evidence of high-grade intraepithelial neoplasia or inva-
sion was found among them. Both these differences were statistically significant as shown by 
p = 0.007 for high grade intraepithelial neoplasia and p < 0.001 for invasive carcinoma [43].
Reference Parameter Total number Mucinous 
differentiation
Marked Weak
Shibata et al. [4] Study group 15 mucinous cystic neoplasms of liver 
(2) and pancreas (13)
6 9
KRAS mutation 6 5 1
Invasive carcinoma 2 2 0
Albores-Saavedra 
et al. [42]
Study group 31 mucinous cystic neoplasms of 
pancreas
22 9
Invasive carcinoma 6 6 0
Zhelnin et al. [43] Study group 136 mucinous cystic neoplasms of liver 





Invasive carcinoma 14 14 0
Albores-Saavedra 
et al. [5]
Study group 20 mucinous cystic neoplasms of liver 
(16) and extrahepatic bile ducts (4)
21 18
High-grade intra-epithelial 
neoplasia and invasive 
carcinoma
2 2 0
1 Along with intestinal differentiation.
Table 4. Clinical and pathogenetic significance of mucinous differentiation in cystic neoplasms with ovarian-type stroma.
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The significance of mucinous differentiation was further clarified by molecular studies. 
KRAS mutations have recently been associated with marked mucinous differentiation and 
malignant transformation [4]. Among 15 mucinous cystic neoplasms of the liver or pancreas, 
KRAS mutations were present in 6 cases, and 5 of them featured marked mucus secretion. 
Thus, the frequency of KRAS mutations in mucinous versus non-mucinous tumours was 83 
versus 11%; p = 0.011. The mutations were found in both invasive cancers (2) and 4 cases 
of low-grade intraepithelial neoplasia [4]. KRAS mutations are confirmed to be the driver 
mutations in the mucinous cystic neoplasms of the liver and pancreas [3]. These genetic 
changes are uncommon in low-grade intraepithelial neoplasia (1/20; 5%) while are present in 
most of cases with invasion, intermediate- or high-grade intraepithelial neoplasia (4/5; 80%; 
p = 0.002). Interestingly, in KRAS-mutated cases that were diagnosed as intermediate- or high-
grade intraepithelial neoplasia, identical mutations were found in adjacent areas of low-grade 
intraepithelial neoplasia. Thus, it seems that KRAS mutations precede and possibly drive the 
morphological changes. In comparison with wild-type tumours, KRAS mutated cases more 
frequently express mucins: MUC1 (pancreatobiliary), MUC2 (intestinal) and MUC5AC (gas-
tric), as reflected by the corresponding p values: p = 0.04; p = 0.016; p = 0.015. By sequencing, 
no alterations of GNAS, RNF43 and PIK3CA have been found in hepatic and pancreatic muci-
nous cystic neoplasms [3]. C-met activation is another pathogenetic event in the mucinous 
cystic neoplasms of the liver [44].
Thus, there is a considerable body of evidence that mucinous epithelium is prone to develop 
high-grade dysplasia and progress to invasive carcinoma. KRAS mutations are likely to be 
a significant driving force within this pathway. Still, different conclusions could follow. 
Albores-Saavedra proposed to reclassify cystic tumours with ovarian type stroma, separat-
ing non-mucinous cystadenomas with pancreatobiliary phenotype and ovarian-like stroma 
in a new entity that hypothetically had no malignant potential [42]. In contrast, Zhelnin 
et al. viewed the mucinous differentiation as a dynamic change: a sign of tumour progres-
sion towards malignancy [43]. The observation that non-mucinous tumours are smaller [43] 
and found in younger patients [4, 43] is in accordance with this assumption. Consequently, 
evidence of marked mucinous differentiation, e.g., by in vivo confocal laser endomicroscopy 
could prompt surgery.
5.4. Immunophenotype of epithelium
Considering the immunophenotype of epithelium, expression of cytokeratins 7, 8, 18 and 19 is 
characteristic in accordance with the biliary differentiation [1, 5]. As was noted, KRAS mutated 
cases more frequently expressed pancreatobiliary (MUC1), intestinal (MUC2) and gastric 
(MUC5AC) mucins [3]. Previously, expression of MUC1 [5] was known, and presence of cyto-
keratin 20, CDX2 and MUC2 was reported in association with intestinal differentiation charac-
terised by presence of goblet cells, columnar absorptive cells and Paneth cells. Notably, cases 
with clear-cut intestinal differentiation frequently show invasion [42, 45]. Proliferation fraction 
by Ki-67 is low in benign cases but increases in the areas of malignant change [45]. Epithelial 
membrane antigen EMA is present [8]. Carcinoembryonic antigen CEA is focally expressed in 
the neoplastic epithelium [8] and thus can be found also in the cyst fluid [46]. Chromogranin-
positive endocrine cells are present both in benign and malignant tumours [1, 8].
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5.5. Ovarian-type stroma
The morphologic appearance of stroma is among the crucial diagnostic criteria of mucinous 
cystic neoplasms. The specific stroma consists of densely growing spindled cells that closely 
resemble ovarian tissues. No cellular atypia or mitotic activity is present in contrast with 
biphasic malignant tumours, e.g., carcinosarcoma or mesothelioma. Sarcomatous stromal 
transformation has been reported in mucinous cystic tumours of the liver and pancreas but is 
distinctly rare [10, 47].
The immunophenotype of stromal cells discloses mesenchymal (vimentin), and myogenic 
(actin and desmin) differentiation along with hormone dependence reflected by expression of 
oestrogen (77% of cystadenomas) and progesterone (100% of cystadenomas) receptors [1, 36]. 
In addition, biliary cystadenomas (13 cases) displayed uniform nuclear reactivity for FOXL2, 
a transcription factor that was expressed in female gonads from the early stages of develop-
ment to normal adult ovarian stroma [36]. Alpha-inhibin also is found [1, 44]. The landscape 
of oestrogen and progesterone receptor expression (Figure 1) along with alpha-inhibin, cal-
retinin and CD10 can be useful in the rare but demanding cases when differential diagnosis 
is between endometriosis and mucinous cystic tumours [48]. Not only the mere presence, 
but location of positive reaction (epithelium versus stroma) is of utmost importance (Table 5).
Three additional morphologic events, occasionally seen in stroma of mucinous cystic neo-
plasms, include luteinisation of stromal cells [1], calcification [10] and xanthogranulomatous 
reaction. The latter features cholesterol crystals (seen in tissue sections as clefts) as well as 
foam cells and lipofuscin-containing macrophages. The outer layer of tumour wall is repre-
sented by loose fibrous tissue [1].
Some authors have emphasised the difficulties in stromal assessment, namely, the focal nature 
of the specific ovarian-type tissues and inter-observer variability [11]. Among 36 mucinous 
cystic neoplasms of the liver and extrahepatic biliary tree, only 47% of cases demonstrated dif-
fuse ovarian-type stroma; the diffuse spread was defined as involving >75% of cyst perimeter 
[15]. To overcome such problems, wide sampling and increased awareness of pathologist 
about mucinous cystic neoplasms will be helpful. In doubt, immunohistochemical visualisa-
tion of oestrogen and progesterone receptors in the stroma can be advised. This finding is not 
Antigen Endometriosis in the liver Mucinous cystic tumour of the liver
Oestrogen receptors + stroma//+ epithelium + stroma//− epithelium
Progesterone receptors + stroma//+ epithelium + stroma//− epithelium
Alpha-inhibin − stroma + stroma
CD10 + stroma − stroma
Cytokeratin 7 + epithelium + epithelium
Cytokeratin 19 + epithelium + epithelium
Abbreviations and symbols in the table: +, positive reaction; −, negative reaction; CD; cluster of differentiation.
Table 5. Immunophenotype of mucinous cystic tumours of the liver versus endometriosis [1, 48].
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entirely specific; endometriosis, in particular, represents another oestrogen- and progesterone 
receptor positive lesion. However, it is useful for the differential diagnosis with simple cyst or 
intraductal papillary neoplasms, both lacking stromal hormone receptor expression.
5.6. FNA, core biopsy and frozen section: findings and limitations
The efficacy of preoperative morphological diagnostics is limited, regarding both core biopsy 
and fine needle aspiration (FNA) for cytology. By FNA, groups of cuboidal or columnar epithe-
lial cells can be observed against either watery or mucinous background. The cellular atypia can 
be variable, depending on the degree of intraepithelial neoplasia and reflecting the heterogene-
ity seen within a single mucinous cystic neoplasm of the liver. As the stromal cells usually are 
not seen in the sample, differential diagnostics with intraductal papillary neoplasm is not reli-
able. FNA of intraductal papillary neoplasms yields papillae with fibrovascular cores; although 
papillary groups can be seen in mucinous cystic neoplasms, they are abundant in intraductal 
papillary neoplasms. Presence of nuclear grooves is also characteristic of intraductal papillary 
neoplasms. In addition to problems in distinguishing between different cystic liver lesions, the 
focality of sampling can decrease sensitivity of FNA for the diagnosis of malignancy [1].
Core biopsy is not advised as the cystic nature of lesions precludes obtaining of a representa-
tive tissue sample. In addition, the heterogeneity represents a further obstacle as the foci of 
invasive growth can easily be missed. Rarely, biopsy can lead to peritoneal carcinomatosis 
therefore it has been advised to avoid biopsy if surgical treatment is planned [10].
For intraoperative diagnostics, the use of frozen section is controversial. The reports range from 
positive experience [49] to high rate (66.6%) of false negative conclusions [40]. Intraoperative 
scrape cytology has been informative in at least one case, revealing both biliary epithelial and 
mesenchymal stromal cells [50].
6. Tumour spread and staging
As was noted, malignant biliary mucinous cystic tumours usually are characterised by lim-
ited growth, invading the fibrous pseudocapsule [38]. Only in rare cases, the tumour widely 
infiltrates the adjacent liver, spreads to regional lymph nodes (mainly in hepatoduodenal 
ligament) or distant organs, such as lungs, pleura or peritoneum [1]. TNM staging is analo-
gous to intrahepatic cholangiocarcinoma (Table 6).
Parameter Definition
T—extent of local tumour spread
Tx Primary tumour cannot be assessed
T0 No evidence of primary liver tumour
Tis Carcinoma in situ
T1 Solitary invasive tumour lacking vascular invasion
T2a Solitary tumour invading blood vessels
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7. Clinical presentation and course
The symptoms and objective findings (Table 7) are non-specific, attributable mainly to the 
presence of slowly growing mass. The clinical course is characterised by insidious onset and 
slow progress, consistent with the gradual advancement of the tumours (but see further for 
exceptions). The mass can distend liver capsule, rupture, bleed, or compress stomach or duo-
denum [10]. Damage of biliary tree or blood vessels is possible via compression or invasion. 
Consequently, benign or malignant tumours can present similarly.
Abdominal pain or discomfort [10] is the most frequent complaint [22]. Pain has been 
reported in 74% (range in different studies: 60–80%) of patients diagnosed with biliary 
cystic tumours while abdominal distention is observed in 26% and nausea/vomiting in 
11% [18]. Approximately 60% of patients complain about pain in right upper abdominal 
quadrant or epigastric area, in combination with increasing abdominal circumference or 




T3 Tumour perforates visceral peritoneum or directly invades extrahepatic tissues and organs
T4 Periductal growth pattern
N—regional lymph node status in regard to metastases
Nx Regional lymph node status cannot be assessed
N0 No metastases in regional lymph nodes
N1 Metastasis in regional lymph nodes has been identified
M—presence or absence of distant metastases
M0 Distant metastasis absent
M1 Distant metastasis present
Stage
I Stage (I) corresponds to T value (T1) in the absence of metastases in regional lymph nodes 
and distant locations: T1 N0 M0
II Stage (II) corresponds to T value (T2) in the absence of metastases in regional lymph nodes 
and distant locations: T2 N0 M0
III Stage (III) corresponds to T value (T3) in the absence of metastases in regional lymph nodes 
and distant locations: T3 N0 M0
IVA Either highly advanced local tumour (T4) or presence of metastases in regional lymph 
nodes (N1) in the absence of distant metastases:
T4 N0 M0 or T1–4 N1 M0
IVB Presence of distant metastases: T1–4 N0–1 M1
Table 6. TNM staging of mucinous cystic neoplasms of the liver [25].
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Bile duct compression [10] or invasion can lead to obstructive jaundice and predispose to 
ascending infection resulting in cholangitis. If the tumour contents are discharged into bile 
ducts, mucobilia is possible. Bleeding to biliary ways results in haemobilia [51]. Biliary symp-
toms are seen in 35% of patients with benign tumours referred to as cystadenomas by WHO 
classification, 2000 [10] and can be responsible for acute presentation or intermittent course, 
in addition to the more classical slowly progressing clinical picture.
Biliary obstruction (caused by the tumour itself, mucobilia with thick mucus or haemobi-
lia with clots) may present as obstructive jaundice, skin itching, biliary colic, cholangitis, 
nausea, fever or steatorrhea. Intermitted course with repeated bouts of jaundice, biliary 
colic or cholangitis has been reported [10]. Notably, obstructive jaundice can be caused 
by benign tumour as biliary cystadenomas with ovarian-type stroma can show expansive 
growth with prolapse into bile duct. The prolapse is seen by endoscopic retrograde chol-
angiopancreatography as an oval-shaped filling defect in the bile duct. To exclude a stone, 
endoscopic ultrasonography and intraductal ultrasonography are useful, since multiple 
septa are found in tumours. At least 17 such cases have been reported in the medical litera-
ture, 2004–2015 [52].
Haemobilia denotes bleeding towards the bile ducts. In general, most cases of haemobilia 
are caused by trauma or iatrogenic injury from percutaneous biliary tract instrumentation. 
Haemobilia as a primary presentation of liver tumour is unusual. In a systematic review of 222 
cases of haemobilia over 3-year period, only 14 cases were caused by tumours. Nevertheless, 
Philip et al. have reported a male patient presenting with anaemia (haemoglobin 6.7 g/dL) and 
recurrent haemobilia confirmed during duodenal endoscopy. Repeated CT and MRI scans 
initially could not identify liver mass. During re-bleeding episode, the mass was found radio-
logically, but its histogenesis remained unclear until postoperative histology [51].
Gastric or duodenal compression may present as slowly progressing upper gastrointestinal 
obstruction with nausea, vomiting, dyspepsia and/or anorexia [10].
Among unusual manifestations, compression of portal vein can lead to portal hypertension 
and ascites in the absence of cirrhosis. Compression/obstruction of the inferior caval vein with 
subsequent bilateral leg oedema has been reported [38].
Clinical symptoms and signs
Dominant Biliary Vascular Other Absent




























Table 7. The clinical manifestations of mucinous cystic neoplasms of the liver.
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In addition, the patients can be asymptomatic. Although it has been noted that mucinous 
cystic neoplasms of the liver “nearly always cause symptoms at the time of presentation” [1], 
this might merely reflect the cases in which diagnosis is reached at the point when patients 
insist on solving the diagnostic enigma after several years of controversial findings. Indeed, 
occasionally the patients have as long clinical history as 10 years [53]. The symptoms are 
likely to be size-dependant; thus, small mucinous cystic neoplasm of the liver can present as 
an incidental finding. Clinically silent presentation is reported in up to 42.1% of cases [22] and 
is expected to become more frequent with increasing availability of medical services. Indeed, 
the frequency of asymptomatic presentation has been noted to range between 30 and 58% 
[38]. The asymptomatic tumours might be revealed as an accidental finding during radiologi-
cal investigation or abdominal surgery for other clinical indications [10].
At least a fraction of patients experiences lengthy diagnostics and relapse after insufficient 
treatment. Thus, Thomas et al., noted that the symptoms lasted in average for 3.1 years; and 
eight of their patients (8/19) had had 20 procedures prior to definitive ablation [18].
8. Radiological findings and differential diagnosis
Cystic neoplasms of the liver are rare while simple liver cysts are common, seen in 2.5–18% 
of population [54]. Radiological investigation is the mainstay of preoperative diagnostics in 
order to discriminate between simple liver cyst and mucinous cystic neoplasm. Estimates of 
the biological potential (benign versus malignant) and differential diagnostics with other cys-
tic lesions, e.g., parasites, abscesses or cystic/necrotic metastases, represent other important 
tasks [28].
The essential methods of liver evaluation include transabdominal ultrasonography (US), 
computed tomography (CT) and magnetic resonance imaging (MRI). Positron emission 
tomography (PET) can be helpful in detecting malignancy. Mucinous cystic neoplasms of the 
liver, as the term emphasises, are cystic and usually large masses (although small tumours 
have been reported). To distinguish these tumours from simple liver cysts, presence and vas-
cularity of internal septa are important. Some authors have found that vascularity of the sep-
tations is more specific than the mere presence of septa, if the differential diagnosis between a 
simple cyst and a mucinous cystic neoplasm of the liver is carried out [18, 24]. Other research 
teams emphasised the importance of finding internal septa that started perpendicularly to 
the outer wall and were not associated with external indentation [55]. CT can better disclose 
the enhanced internal septations even if they are thin; the cyst content is usually hypoattenu-
ating [56]. By contrast-enhanced ultrasound (CEUS) imaging, biliary cystic tumours mostly 
(78.3%) display honeycomb enhancement pattern of the cyst wall, septa or mural nodules 
[14]. Prolonged enhancement in Kupffer phase is not characteristic but occasionally can be 
caused by rich presence of macrophages [57]. On MRI, mucinous cystic tumours are hypoat-
tenuating on T1W1; however, high protein content in cyst fluid might increase the signal 
intensity. On T2W1, the fluid is hyperintense, and septations are better visible [56]. In addi-
tion, mucinous cystic neoplasms more frequently are solitary if compared with simple liver 
cysts [58]. Synchronous cases represent an unusual exception [59].
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In turn, presence of enhanced mural or septal nodules is the most important sign of malig-
nancy [38]. In contrast, benign cystic tumours have smooth and thin walls and internal septa. 
Calcification in the mural nodules is a controversial finding—some but not all [24, 60, 61] 
authors associate it with malignant tumour (in the context of mucinous cystic neoplasms of 
the liver). By CEUS, benign tumours are characterised by hyperenhancement of the honey-
combed septa during arterial phase (p = 0.047) while malignant cases feature significantly 
(p = 0.041) more frequent hypoenhancement during the portal venous and late phases [14]. 
The experience with PET is very limited, but the reported data reflect correct identification of 
malignant process [18, 38].
Simple cysts are asymptomatic, single or multiple lesions with thin wall and watery con-
tents. Thus, in CT or MRI simple cysts are seen as non-enhancing, well circumscribed, fluid-
containing foci [38]. Multiple cysts can be present in patients affected by autosomal dominant 
polycystic liver disease, and these cases are more prone to haemorrhage. MRI can be helpful 
to identify it thus solving the differential diagnosis. The autosomal recessive Caroli disease 
represents another inherited liver disease associated with cyst development. In Caroli dis-
ease, cavernous ectasias of bile ducts develop, frequently associated with stone formation. 
Radiologically, communications between the cystic cavities and biliary duct system are 
important. “Central dot” sign is observed by CT. Bridges across the cavities are evident by 
MRI. Both these findings represent branches of portal vein embedded in connective tissue 
strands adjacent to and surrounded by dilated bile ducts [28].
Embryonal sarcoma, a rare and usually solid malignant tumour of adolescence, occasionally 
has cyst-like appearance on CT and MRI because of myxoid stroma. Both the age and the 
presence of wide solid component are helpful to exclude mucinous cystic neoplasm of the 
liver [28].
Other malignant tumours, especially metastases, occasionally have cyst-like appearance 
because of necrosis or accumulation of mucus. Necrotic metastases are seen in CT or MRI 
as foci with strong peripheral enhancement and irregular border; usually there are multiple 
lesions. Mucinous metastases most frequently represent metastatic colorectal or ovarian 
carcinoma. In the latter case, the characteristic transperitoneal spread by implantation can 
lead to development of multiple nodules within the liver capsule while mucinous cystic neo-
plasms of the liver are located within liver parenchyma. Neo-adjuvant treatment sometimes 
induces cyst-like degeneration of metastases [62]. On rare occasions, other malignant tumours 
develop unusual cystic appearance, e.g., angiosarcoma [63], Ewing sarcoma [64], primary or 
metastatic neuroendocrine neoplasm [62, 65] or hepatocellular carcinoma [66].
Multiple cystic liver lesions are seen in echinococcosis, characterised by multi-layered wall of 
the cysts and presence of multiple small hypoattenuating daughter cysts with thin eggshell 
calcifications. Serologic tests will confirm the diagnosis [28].
Liver abscess initially is seen as a cluster of small foci that later converge into an unilocular 
cystic lesion. It might contain gas formed by microbial flora. Later, thick, enhancing wall 
develops. “Double target” sign can be evident because of peripheral rim enhancement attrib-
utable to increased capillary permeability. However, invasive growth of malignant tumours 
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can incite similar inflammatory response. Presence of mobile debris seen by US is character-
istic of abscess [28].
History of trauma or operation is helpful to suspect a bile collection (biloma) or hematoma. 
Biloma is visible in CT and MRI as a well-demarcated cystic focus lacking septa, calcifications 
or pseudocapsule [28].
9. Assessment of cyst fluid
Regarding the analysis of cyst fluid, the diagnostic value is controversial. Promising 
reports have suggested that high concentrations of certain proteins in the cyst fluid might 
help to distinguish cystic tumours from simple cysts thus aiding in case selection for sur-
gery. Assessment of cyst fluid would be free of problems related to sampling of heteroge-
neous tissues—a frequent problem in obtaining and interpretation of biopsy. Elevated 
levels of carbohydrate antigen CA19-9, significantly exceeding the concentration of 
CA19-9 in the serum, have been reported in cyst fluid [22]. Increased concentrations of 
CEA and CA19-9 in the cyst fluid are described in cystic tumours but not in simple liver 
cysts [46]. However, comparing the levels of CA19-9, CEA and cancer antigen 125, no 
significant differences (p = 0.45; p = 0.49 and p = 0.73, respectively) were found between 
13 mucinous cystic neoplasms and 38 simple hepatic cysts [58]. Still, in a larger group includ-
ing 32 mucinous cystic tumours and 40 simple cysts, a significantly elevated CA19-9 level in 
tumours was shown. The differences were demonstrated both by the median level of CA19-9 
(364.8 versus 21.4 U/mL) and the fraction of cases in which CA19-9 exceeded the highest value 
of laboratory reference interval for serum assessment (46.9 versus 10.0%). The concentra-
tions of CEA lacked significant difference; the median value was 6.8 mg/L in tumours versus 
4.2 mg/L in simple cysts [67]. Tumour-associated glycoprotein (TAG) 72 has been suggested as 
a highly informative marker for differential diagnosis between mucinous cystic tumours and 
simple liver cysts. Performing ROC curve analysis, TAG-72 concentration exceeding 25 U/mL 
was associated with specificity and sensitivity of 0.97 and 0.79, respectively, being superior to 
CEA and CA19-9 and yielding area under curve (AUC) of 0.98 for the discrimination between 
cystic tumours and simple cysts [68].
Regarding pancreatic counterparts, attractive future research directions have appeared regard-
ing diagnostics by cyst fluid assessment, e.g., next generation sequencing for driver mutations 
(e.g., KRAS) in the cyst content [69], combined evaluation of CEA and KRAS status [70]; or 
CEA, CA19-9, cytological and ultrasonographic findings [71]. Elaboration of combined diag-
nostic algorithms based on several features, including detection of tumour markers, viscosity 
[72], mucinous differentiation [73], KRAS testing, proteome analysis [74] in the cyst fluid and 
ultrasound or CT features, is pathogenetically substantiated, up-to-date [75] and promising 
direction. However, any preoperative cyst sampling involves low but not negligible risk of 
complications, including peritoneal or pleural dissemination, or pseudomyxoma in malig-
nant cases [20]. In addition, the differential diagnostic background in pancreas also differs 
from liver—an organ, affected by simple cysts in up to 18% of the general population [54].




Once the diagnosis of a mucinous cystic liver neoplasm has been established, surgery is the 
mainstay of the treatment. These tumours have two essential biological features: (1) capacity 
to recur after incomplete excision and (2) slow progression towards malignant transformation, 
seen with reasonable frequency [10]. Therefore complete surgical resection is strongly advised. 
The intent must be to remove all the neoplastic tissues. However, considering the low biologi-
cal potential of these neoplasms, wide resection margin is not mandatory. Thus, enucleation or 
liver resection (hepatectomy, bisegmentectomy and extended hepatectomy) represent appro-
priate approaches while marsupialisation, internal Roux-en-Y drainage, aspiration, sclerosing 
or partial resection are associated with high rate of complications, mainly recurrence or sepsis 
[18, 20, 28]. Enucleation with clear margins is the preferable option for large central tumours, 
associated with/located close to blood vessels or large bile ducts [20]. Liver transplantation has 
been suggested in unresectable cases including recurrent or giant tumours [61, 76].
The recurrence rate after an incomplete resection is as high as 90% therefore an undiagnosed 
mucinous cystic liver neoplasm should be suspected in any patient who experiences a relapse 
after treatment of presumed simple liver cyst, e.g., marsupialisation (deroofing) or partial 
resection [20]. Although such recurrences bring the risk of malignant change, the biological 
potential of mucinous cystic tumours is low and recurrent patients still are amenable to sur-
gery, even after repeated relapses and over as long time period as 10 years [18, 20, 53].
There is very limited experience with treatment other than surgery. Argon beam plasma 
coagulation has occasionally been used as an adjunct to surgery. A case of biliary cystadeno-
carcinoma has been reported in which the main focus was removed by non-anatomic liver 
resection while a satellite lesion underwent fulguration. The patient experienced prolonged 
survival and was free of disease 2142 days (5.9 years) after operation [18].
The data on the efficacy of primary or adjuvant chemo-/radiotherapy are limited to few case 
reports. For instance, systemic, 5-fluoruracil-based chemotherapy was reported effective in a sin-
gle patient who had recurrence and multiple metastases of biliary cystadenocarcinoma 41 months 
after surgical removal. The patient benefitted from tumour reduction and clinical improvement 
[28]. In another patient, major hepatectomy was not amenable because of insufficient functional 
reserve of the liver, but hepatic arterial infusion of cisplatin helped to reduce the size of the 
tumour from 12 cm in diameter to 2 cm and to improve the general condition [77]. Three patients 
have received chemo-radiotherapy as a primary treatment. The 2-year and 5-year survival was 
33.3% [39]. Currently, the reported experience with chemotherapy is clearly insufficient.
11. Prognosis
Exact prognostic data are difficult to obtain because of two problems: (1) rarity of mucinous 
cystic tumours leading to predominantly small study groups and (2) contamination of even 
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these cohorts with cases lacking ovarian-type stroma. As shown further, as least a fraction of 
tumours lacking the specific stroma might represent intraductal papillary neoplasms that are 
associated with worse outcome. However, general lines still can be drawn.
The prognosis depends both on the presence or absence of invasion [78] and metastatic 
spread (albeit rare) as well as on the completeness of resection. After complete removal of 
a benign tumour, the prognosis is excellent. The overall survival is 90% over 18 years [13]. 
Zen et al. reported on 24 surgically treated cases; all patients were alive during follow-up of 
1–132 months; median 47 months [21]. Some authors have not experienced recurrence of a 
benign cystic mucinous tumour after appropriate surgical treatment while others note the risk 
of recurrence ranging between 5 and 13% [13, 21]. Incomplete surgical removal leads to recur-
rence [18, 21]. In untreated cases or in patients subjected to non-radical approach, malignant 
change can develop; the risk is estimated to be as high as 20% [13].
Although malignant tumours can recur after surgery, the prognosis of surgically removed 
invasive mucinous cystic tumour of the liver is significantly better than for other primary 
malignant liver tumours, including hepatocellular carcinoma or cholangiocarcinoma. 
Prolonged survival can be expected. Even disease-free survival after radical resection of 
cystadenocarcinoma was 16.5 and 33 months [22]. The 5-year survival of surgically resected 
malignant mucinous cystic tumour of the liver is 65–70%, contrasting with 40% in hepatocel-
lular carcinoma and 22% in cholangiocarcinoma [13]. If relapse develops, mostly it is local, but 
some patients (up to 20%) experience extrahepatic metastases [13].
Mucinous cystic tumours of the liver are associated with better prognosis than intraductal 
papillary tumours. After resection of mucinous cystic neoplasm of the liver, 5-year survival 
rate was 100%, contrasting with 84% in patients diagnosed with intraductal papillary neo-
plasm of bile duct [79]. Similarly, the 5-year survival of surgically treated hepatic mucinous 
cystic neoplasms (13) including malignant cases (38.5%) was 100%, exceeding the outcome of 
intraductal papillary neoplasms: 5-year survival rate in this group was 82% [41].
12. Conclusions
Mucinous cystic neoplasms of the liver, formerly known as biliary cystadenoma and cystad-
enocarcinoma in accordance with WHO classification (2000), have been redefined by WHO 
(2010) as epithelial cystic neoplasms with ovarian-like stroma. They are subclassified by the 
presence or absence of invasion. Non-invasive cases are further distinguished by the highest 
grade of intraepithelial neoplasia.
Although the exact incidence has to be clarified in subsequent studies, mucinous cystic neo-
plasms of the liver are rare. Previously, the incidence of biliary cystadenoma was estimated 
to range between 1:20,000 and 1:100,000, while the incidence of biliary cystadenocarcinoma 
was reported to be 1:10 million. Considering the whole group of hepatic and biliary mucinous 
cystic neoplasms with ovarian-type stroma, 25% of cases that were previously diagnosed as 
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biliary cystadenoma/cystadenocarcinoma might be reclassified as other entities according to 
the current WHO classification.
The origin of these tumours is unclear. The best substantiated hypotheses point towards 
peribiliary origin, possibly in association with ectopic ovarian stroma or remnants of 
embryonal gall bladder or foregut tissues. The most important advances in morphologic and 
molecular studies include mucinous differentiation as a progression phenomenon, indicat-
ing development towards malignancy and identification of KRAS mutations as the molecular 
driver force.
The clinical presentation is unspecific. Mass effects are dominant, leading to abdominal pain 
or discomfort. Biliary obstruction can be seen both in benign and malignant cases, being 
caused by expansive growth and prolapse into biliary ways or by invasion, respectively. 
Biliary symptoms are observed in 35% of patients and include obstructive jaundice, skin itch-
ing, biliary colic, cholangitis, mucobilia, haemobilia, nausea, fever or steatorrhea. Bile duct 
involvement can be responsible for acute presentation or intermittent course, in addition to 
the more classical slowly progressing clinical picture.
Radiological evaluation is the mainstay of diagnostics, as both FNA and core biopsy have 
limited informativity. The essential methods of liver evaluation include transabdominal ultra-
sonography, computed tomography, magnetic resonance imaging and positron emission 
tomography. Mucinous cystic neoplasms of the liver are cystic, usually large and solitary. 
To distinguish these tumours from simple liver cysts, presence and vascularity of internal 
septa are important. In turn, presence of enhanced mural or septal nodules is the most impor-
tant sign of malignancy. Calcification in the mural nodules can indicate malignancy, but is 
controversial. The experience with PET is very limited, but the reported data reflect correct 
identification of malignant process.
In turn, radical surgery is the main treatment option. The intent is to remove all the neo-
plastic tissues. However, considering the low biological potential of these neoplasms, wide 
resection margin is not mandatory. Thus, enucleation or liver resection represent appropri-
ate approaches while marsupialisation, internal Roux-en-Y drainage aspiration, sclerosing or 
partial resection are associated with high rate of complications, mainly recurrence or sepsis. 
After complete resection of non-invasive tumours, the prognosis is excellent. Prolonged sur-
vival can be expected even in invasive cases.
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